Johnson & Johnson Stock (US4781601046): Q1 Beats, Guidance Raised as Shares Trade Near $225 on NYSE

Johnson & Johnson has reported first?quarter results that slightly exceeded analyst expectations, with earnings per share of $2.70 on revenue of $24.06 billion, according to company disclosures and secondary coverage of the earnings release. The firm also raised its full?year 2026 adjusted EPS guidance to a range of $11.45–$11.65 and increased its quarterly dividend to $1.34 per share, or $5.36 on an annualized basis, which corresponds to a yield of about 2.4% at current prices.

As of the latest available data, Johnson & Johnson stock traded near $225 on the New York Stock Exchange, reflecting a modest decline versus recent highs but still well above its 52?week low. The company’s market capitalization stands at roughly $535 billion, with a price?to?earnings multiple in the mid?20s and a beta below 0.3, indicating relatively low volatility versus the broader market.

Johnson & Johnson’s first?quarter revenue of $24.06 billion represented a year?over?year increase of 9.9%, according to the company’s earnings materials and corroborating secondary sources. Adjusted net income for the quarter translated into EPS of $2.70, compared with a consensus estimate of $2.68 and prior?year EPS of $2.77. The firm’s net margin was reported at about 21.8%, with return on equity around 32.6%, underscoring continued profitability despite ongoing portfolio transitions.

The company has maintained a diversified structure across pharmaceuticals, medical devices, and consumer health, with pharmaceuticals now the largest segment following the spin?off of Kenvue. In the first quarter, pharmaceutical sales growth was driven by immunology products such as TREMFYA and other established brands, while medical devices benefited from recovery in elective procedures and new product launches. Consumer health, though smaller in absolute terms, continues to contribute stable cash flow from over?the?counter brands.

Management has reiterated a focus on innovation and pipeline advancement, highlighting positive Phase 3 data for TREMFYA in additional indications and encouraging Phase 2b results for the investigational co?antibody JNJ?4804 in refractory inflammatory bowel disease. The company also reported that its Ottava surgical robot met endpoints in a pivotal bariatric study, signaling progress in its robotics and advanced?surgery portfolio. These developments support long?term growth but are not yet fully reflected in current earnings.

At the same time, Johnson & Johnson faces near?term headwinds, including payer pressure on high?cost biologics. CVS has announced plans to remove Stelara from its main formularies in favor of lower?cost interchangeable biosimilars starting in July, which could weigh on Stelara sales and create short?term uncertainty around immunology revenue. Analysts note that while the broader immunology franchise remains strong, any erosion in Stelara share could pressure near?term growth and margins.

Against this backdrop, the company has raised its 2026 adjusted EPS guidance to $11.45–$11.65, implying modest growth versus prior guidance and reflecting both underlying business momentum and the impact of portfolio changes. Sell?side analysts currently project full?year EPS of about $11.57, in line with management’s midpoint. Revenue growth for the year is expected to remain in the mid?single?digit range, with pharmaceuticals outpacing medical devices and consumer health.

Dividend policy remains a key feature for income?oriented investors. Johnson & Johnson has increased its quarterly payout to $1.34 per share, maintaining its status as a Dividend Aristocrat with a long history of consecutive annual increases. At a current yield of roughly 2.4%, the dividend sits below the broader market average but is supported by strong cash flow and a payout ratio that remains within historical norms for the company.

From a valuation perspective, Johnson & Johnson trades at a premium to many large?cap peers, with a P/E ratio in the mid?20s and a PEG ratio above 2.0, according to widely cited market data providers. Analysts point out that the premium reflects the company’s diversified business model, global scale, and defensive characteristics, but also leaves limited room for multiple expansion if growth disappoints. Shares currently trade below the consensus 12?month price target of about $252, implying upside potential if the company meets or exceeds its guidance.

Several large institutions have recently adjusted their positions in Johnson & Johnson. QRG Capital Management increased its stake by about 10% in the fourth quarter, raising its holding to roughly 388,781 shares with a market value of about $80 million. Principal Financial Group also added to its position, purchasing more than 28,000 shares to bring its total to over 3.4 million shares worth approximately $705 million. These moves suggest continued institutional confidence in the company’s long?term prospects despite near?term challenges.

On the sell side, multiple brokerages have revised their price targets upward in recent weeks. HSBC raised its target from $265 to $280 and maintained a buy rating, while Argus lifted its target from $240 to $275 with a buy recommendation. Guggenheim increased its target from $244 to $266, and JPMorgan Chase raised its target from $250 to $260 with a neutral stance. Royal Bank of Canada reiterated an outperform rating with a $265 target. Collectively, these actions support a consensus “moderate buy” stance with an average target in the mid?$250s.

For US investors, Johnson & Johnson offers exposure to a large?cap, dividend?paying healthcare company with significant operations in the United States. The stock is listed on the NYSE under the ticker JNJ and trades in US dollars, with SEC filings and investor?relations materials available in English. The company derives a substantial portion of its revenue from the US market, particularly in pharmaceuticals and medical devices, which enhances its relevance for domestic portfolios.

Investors considering Johnson & Johnson should weigh the balance between defensive characteristics and growth constraints. The company’s diversified portfolio, strong cash flow, and dividend history provide stability, but exposure to biosimilar competition, regulatory scrutiny, and pricing pressure in key therapeutic areas introduces risk. Pipeline progress in immunology, oncology, and advanced?surgery technologies could drive future growth, while any setbacks in clinical trials or commercial execution could weigh on sentiment.

Looking ahead, key events for investors include the next quarterly earnings release, scheduled for later in the year, and any updates on pipeline milestones or regulatory decisions. Management’s commentary on Stelara’s trajectory in light of CVS’s formulary changes, as well as progress on new product launches and cost?management initiatives, will be closely watched. The company’s ability to maintain or expand margins while investing in innovation will likely determine whether the current valuation premium is justified over the medium term.

In summary, Johnson & Johnson’s first?quarter results and raised guidance reflect resilience in a complex healthcare environment, with solid revenue growth, continued profitability, and a commitment to shareholder returns through dividends. The stock trades near $225 on the NYSE, below the consensus price target but at a premium to many peers, reflecting both its defensive profile and growth expectations. Investors should monitor pipeline developments, payer dynamics, and margin trends as they assess the company’s long?term prospects.